Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 3, 2015, Pages 522-530.e2

  Yanai, Henit ^a,b   Lichtenstein, Lev ^b,c   Assa, Amit ^b,d   Mazor, Yoav ^e   Weiss, Batia ^b,f   Levine, Arie ^b,g   Ron, Yulia ^a,b   Kopylov, Uri ^b,h   Bujanover, Yoram ^b,f   Rosenbach, Yoram ^b,d   Ungar, Bella ^b,h   Eliakim, Rami ^b,h   Chowers, Yehuda ^e   Shamir, Raanan ^b,d   Fraser, Gerald ^b,c   Dotan, Iris ^a,b   Ben Horin, Shomron ^b,h  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^f Edmond and Lily Safra Children's Hospital   (Israel)

^g WOLFSON MEDICAL CENTER   (Israel)

^h SHEBA MEDICAL CENTER   (Israel)

Author keywords

Anti TNF antibodies; Crohn's disease; IBD; UC

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; DRUG ANTIBODY; INFLIXIMAB; ANTIBODY; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; COHORT ANALYSIS; CROHN DISEASE; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MONITORING; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; ISRAEL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; TRAFFIC ACCIDENT; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; TREATMENT FAILURE; YOUNG ADULT;

ADALIMUMAB; ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; ISRAEL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84925367939     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.07.029     Document Type: Article

References (28)

1. Ben-Horin S., Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011, 33:987-995.
2. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011, 106:674-684.
3. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
4. Ainsworth M.A., Bendtzen K., Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008, 103:944-948.
5. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEngl J Med 2003, 348:601-608.
6. Ben-Horin S., Yavzori M., Katz L., et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011, 60:41-48.
7. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
8. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
9. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
10. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
11. Allez M., Karmiris K., Louis E., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. JCrohns Colitis 2010, 4:355-366.
12. Colombel J.F., Feagan B.G., Sandborn W.J., et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:349-358.
13. Ordas I., Feagan B.G., Sandborn W.J. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10:1079-1087. quiz e85-e86.
14. Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011, 106:685-698.
15. Afif W., Loftus E.V., Faubion W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
16. Pariente B., Pineton de Chambrun G., Krzysiek R., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:1199-1206.
17. Vande Casteele N., Gils A., Singh S., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013, 108:962-971.
18. Regueiro M., Siemanowski B., Kip K.E., et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007, 13:1093-1099.
19. Katz L., Gisbert J.P., Manoogian B., et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012, 18:2026-2033.
20. Khanna R., Sattin B.D., Afif W., et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther 2013, 38:447-459.
21. Steenholdt C., Brynskov J., Thomsen O.O., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014, 63:919-927.
22. Sandborn W.J., Colombel J.F., Schreiber S., et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011, 17:141-151.
23. Steenholdt C., Al-khalaf M., Brynskov J., et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2209-2217.
24. Ungar B., Chowers Y., Yavzori M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014, 63:1258-1264.
25. Kopylov U., Mazor Y., Yavzori M., et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012, 18:1628-1633.
26. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013, 108:40-47. quiz 48.
27. Imaeda H., Takahashi K., Fujimoto T., et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. JGastroenterol 2014, 49:100-109.
28. Roblin X., Marotte H., Rinaudo M., et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014, 12:80-84.e2.